Cellectis (CLLS) Competitors

$4.07 +0.09 (+2.14%)

Closing price 03:59 PM Eastern

Extended Trading

$4.07 0.00 (0.00%)

As of 04:04 PM Eastern

CLLS vs. AMLX, ARDX, IOVA, INBX, and IMTX

Should you buy Cellectis stock or one of its competitors? MarketBeat compares Cellectis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cellectis include Amylyx Pharmaceuticals (AMLX), Ardelyx (ARDX), Iovance Biotherapeutics (IOVA), Inhibrx Biosciences (INBX), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry.

How does Cellectis compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Amylyx Pharmaceuticals' return on equity of -55.69% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Cellectis	-89.51%	-80.66%	-20.51%

Cellectis has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	17.66	-$144.74M	-$1.50	N/A
Cellectis	$72.95M	5.59	-$67.59M	-$0.67	N/A

Amylyx Pharmaceuticals has a beta of -0.11, meaning that its stock price is 111% less volatile than the broader market. Comparatively, Cellectis has a beta of 2.94, meaning that its stock price is 194% more volatile than the broader market.

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Amylyx Pharmaceuticals had 8 more articles in the media than Cellectis. MarketBeat recorded 14 mentions for Amylyx Pharmaceuticals and 6 mentions for Cellectis. Cellectis' average media sentiment score of 0.93 beat Amylyx Pharmaceuticals' score of -0.10 indicating that Cellectis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectis	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals presently has a consensus target price of $23.00, indicating a potential upside of 65.71%. Cellectis has a consensus target price of $6.75, indicating a potential upside of 66.05%. Given Cellectis' stronger consensus rating and higher probable upside, analysts plainly believe Cellectis is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Cellectis beats Amylyx Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Cellectis compare to Ardelyx?

Ardelyx (NASDAQ:ARDX) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ardelyx presently has a consensus target price of $15.70, indicating a potential upside of 143.03%. Cellectis has a consensus target price of $6.75, indicating a potential upside of 66.05%. Given Ardelyx's stronger consensus rating and higher probable upside, equities analysts plainly believe Ardelyx is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Ardelyx has a net margin of -13.58% compared to Cellectis' net margin of -89.51%. Ardelyx's return on equity of -38.11% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Cellectis	-89.51%	-80.66%	-20.51%

Ardelyx has higher revenue and earnings than Cellectis. Ardelyx is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$427.68M	3.73	-$61.60M	-$0.23	N/A
Cellectis	$72.95M	5.59	-$67.59M	-$0.67	N/A

Ardelyx has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Cellectis has a beta of 2.94, meaning that its stock price is 194% more volatile than the broader market.

In the previous week, Ardelyx and Ardelyx both had 6 articles in the media. Ardelyx's average media sentiment score of 1.05 beat Cellectis' score of 0.93 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectis	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ardelyx beats Cellectis on 10 of the 15 factors compared between the two stocks.

How does Cellectis compare to Iovance Biotherapeutics?

Cellectis (NASDAQ:CLLS) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cellectis currently has a consensus target price of $6.75, indicating a potential upside of 66.05%. Iovance Biotherapeutics has a consensus target price of $8.43, indicating a potential upside of 139.45%. Given Iovance Biotherapeutics' higher possible upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

Cellectis has a net margin of -89.51% compared to Iovance Biotherapeutics' net margin of -123.92%. Iovance Biotherapeutics' return on equity of -50.17% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Cellectis has higher earnings, but lower revenue than Iovance Biotherapeutics. Cellectis is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$72.95M	5.59	-$67.59M	-$0.67	N/A
Iovance Biotherapeutics	$285.61M	5.50	-$390.98M	-$0.95	N/A

Cellectis has a beta of 2.94, meaning that its share price is 194% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

In the previous week, Iovance Biotherapeutics had 11 more articles in the media than Cellectis. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 6 mentions for Cellectis. Cellectis' average media sentiment score of 0.93 beat Iovance Biotherapeutics' score of 0.26 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cellectis beats Iovance Biotherapeutics on 10 of the 17 factors compared between the two stocks.

How does Cellectis compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Inhibrx Biosciences currently has a consensus target price of $150.00, suggesting a potential upside of 29.13%. Cellectis has a consensus target price of $6.75, suggesting a potential upside of 66.05%. Given Cellectis' stronger consensus rating and higher probable upside, analysts plainly believe Cellectis is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Cellectis has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,305.19	-$140.05M	-$9.04	N/A
Cellectis	$72.95M	5.59	-$67.59M	-$0.67	N/A

Inhibrx Biosciences has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Cellectis' return on equity of -80.66% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-269.56%	-71.94%
Cellectis	-89.51%	-80.66%	-20.51%

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 17.1% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Inhibrx Biosciences had 5 more articles in the media than Cellectis. MarketBeat recorded 11 mentions for Inhibrx Biosciences and 6 mentions for Cellectis. Cellectis' average media sentiment score of 0.93 beat Inhibrx Biosciences' score of 0.23 indicating that Cellectis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectis	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences has a beta of 3.88, suggesting that its share price is 288% more volatile than the broader market. Comparatively, Cellectis has a beta of 2.94, suggesting that its share price is 194% more volatile than the broader market.

Summary

Cellectis beats Inhibrx Biosciences on 10 of the 16 factors compared between the two stocks.

How does Cellectis compare to Immatics?

Cellectis (NASDAQ:CLLS) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

Cellectis has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$72.95M	5.59	-$67.59M	-$0.67	N/A
Immatics	$54.60M	27.43	-$222.26M	-$1.84	N/A

In the previous week, Cellectis had 1 more articles in the media than Immatics. MarketBeat recorded 6 mentions for Cellectis and 5 mentions for Immatics. Cellectis' average media sentiment score of 0.93 beat Immatics' score of -0.35 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immatics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cellectis currently has a consensus price target of $6.75, indicating a potential upside of 66.05%. Immatics has a consensus price target of $19.00, indicating a potential upside of 70.10%. Given Immatics' higher possible upside, analysts plainly believe Immatics is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Immatics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Cellectis has a beta of 2.94, indicating that its share price is 194% more volatile than the broader market. Comparatively, Immatics has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

63.9% of Cellectis shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 3.3% of Immatics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cellectis has a net margin of -89.51% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.65% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
Immatics	-572.35%	-47.65%	-39.46%

Summary

Cellectis beats Immatics on 11 of the 17 factors compared between the two stocks.

Get Cellectis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLLS vs. The Competition

Export

Metric	Cellectis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$407.88M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-6.07	18.81	20.87	25.61
Price / Sales	5.59	181.76	521.62	63.45
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	6.78	6.75	9.86	6.71
Net Income	-$67.59M	$24.11M	$3.55B	$333.77M
7 Day Performance	5.31%	0.11%	-0.26%	0.40%
1 Month Performance	-2.28%	0.87%	1.39%	4.03%
1 Year Performance	194.57%	78.18%	41.07%	36.33%

Cellectis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLLS Cellectis	2.8699 of 5 stars	$4.07 +2.1%	$6.75 +66.1%	+182.3%	$407.88M	$72.95M	N/A	290	Earnings Report Gap Up
AMLX Amylyx Pharmaceuticals	2.6506 of 5 stars	$14.53 -2.4%	$23.00 +58.3%	+224.7%	$1.61B	$87.37M	N/A	200	Trending News Earnings Report Analyst Revision
ARDX Ardelyx	4.3438 of 5 stars	$6.54 -1.1%	$15.70 +140.2%	+88.2%	$1.61B	$407.32M	N/A	90	Positive News
IOVA Iovance Biotherapeutics	2.8458 of 5 stars	$3.54 -4.5%	$8.43 +138.4%	+104.5%	$1.59B	$263.50M	N/A	500	Earnings Report Analyst Revision
INBX Inhibrx Biosciences	2.6941 of 5 stars	$103.77 -18.7%	$150.00 +44.6%	+945.7%	$1.54B	$1.30M	N/A	166

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLLS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectis (CLLS) Competitors

CLLS vs. AMLX, ARDX, IOVA, INBX, and IMTX

How does Cellectis compare to Amylyx Pharmaceuticals?

Summary

How does Cellectis compare to Ardelyx?

Summary

How does Cellectis compare to Iovance Biotherapeutics?

Summary

How does Cellectis compare to Inhibrx Biosciences?

Summary

How does Cellectis compare to Immatics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS vs. The Competition

Cellectis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cellectis (CLLS) Competitors

CLLS vs. AMLX, ARDX, IOVA, INBX, and IMTX

How does Cellectis compare to Amylyx Pharmaceuticals?

Is AMLX or CLLS more profitable?

Which has better valuation & earnings, AMLX or CLLS?

Which has more risk & volatility, AMLX or CLLS?

Do institutionals and insiders have more ownership in AMLX or CLLS?

Does the media refer more to AMLX or CLLS?

Do analysts rate AMLX or CLLS?

Summary

How does Cellectis compare to Ardelyx?

Do institutionals and insiders have more ownership in ARDX or CLLS?

Do analysts rate ARDX or CLLS?

Is ARDX or CLLS more profitable?

Which has better valuation & earnings, ARDX or CLLS?

Which has more risk & volatility, ARDX or CLLS?

Does the media refer more to ARDX or CLLS?

Summary

How does Cellectis compare to Iovance Biotherapeutics?

Do insiders & institutionals have more ownership in CLLS or IOVA?

Do analysts rate CLLS or IOVA?

Is CLLS or IOVA more profitable?

Which has preferable valuation and earnings, CLLS or IOVA?

Which has more volatility and risk, CLLS or IOVA?

Does the media refer more to CLLS or IOVA?

Summary

How does Cellectis compare to Inhibrx Biosciences?

Do analysts prefer INBX or CLLS?

Which has higher earnings & valuation, INBX or CLLS?

Is INBX or CLLS more profitable?

Do institutionals & insiders hold more shares of INBX or CLLS?

Does the media favor INBX or CLLS?

Which has more volatility and risk, INBX or CLLS?

Summary

How does Cellectis compare to Immatics?

Which has better earnings & valuation, CLLS or IMTX?

Does the media refer more to CLLS or IMTX?

Do analysts prefer CLLS or IMTX?

Which has more volatility & risk, CLLS or IMTX?

Do institutionals and insiders have more ownership in CLLS or IMTX?

Is CLLS or IMTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS vs. The Competition

Cellectis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools